“We believe that MNTA’s technology will enable us to uniquely demonstrate equivalence to innovative products. Out intent is to develop FoB’s that are not simply biosimilar but have the potential to be biogenerics, interchangeable and substitutable for the branded biologics.”
—Craig Wheeler, CEO (from 2/14/08 CC)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.